Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
14.22
+0.08 (0.57%)
At close: Jan 31, 2025, 4:00 PM
14.21
-0.01 (-0.07%)
After-hours: Jan 31, 2025, 5:12 PM EST
Dyne Therapeutics Employees
Dyne Therapeutics had 141 employees as of December 31, 2023. The number of employees increased by 22 or 18.49% compared to the previous year.
Employees
141
Change (1Y)
22
Growth (1Y)
18.49%
Revenue / Employee
n/a
Profits / Employee
-$2,088,752
Market Cap
1.45B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 141 | 22 | 18.49% |
Dec 31, 2022 | 119 | 26 | 27.96% |
Dec 31, 2021 | 93 | 46 | 97.87% |
Dec 31, 2020 | 47 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
DYN News
- 11 days ago - Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 - GlobeNewsWire
- 21 days ago - Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? - Benzinga
- 22 days ago - Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 - GlobeNewsWire
- 23 days ago - Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 23 days ago - Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - GlobeNewsWire
- 2 months ago - Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases - Seeking Alpha
- 3 months ago - Dyne Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Possible Securities Law Violations - Accesswire